Literature DB >> 33710365

Antibiotic administration for negative midstream urine culture patients before percutaneous nephrolithotomy.

Cheng He1, Hequn Chen1, Yang Li1, Feng Zeng1, Yu Cui1, Zhiyong Chen2.   

Abstract

To investigate how to administrate antibiotics for negative midstream urine culture (UC-) patients prior to percutaneous nephrolithotomy (PCNL), we retrospectively analyzed UC-patients receiving 0 or 3 days of cefuroxime prior to PCNL between July 2017 and May 2020. Patients were further divided into four groups (Group1A = urine with positive both nitrite and white blood cell (N + WBC +) and 0-day pre-operative cefuroxime; Group1B = N + WBC + and 3-day cefuroxime; Group2A = N - WBC + and 0-day cefuroxime; Group2B = N - WBC + and 3-day cefuroxime). All patients routinely received a dose of cefuroxime 30 min prior to the surgery. In addition, Group1B were matched to the Group1A; Group2B were matched to the Group2A at a 1:1 ratio regarding stone burden, the degree of hydronephrosis, stone hardness, age and sex in a sequential order. A total of 560 patients were included (Group1A = 72; Group1B = 72; Group2A = 208; Group2B = 208). The baseline characteristics were equally distributed between the matched-pair groups. Compared to Group1B, Group1A had a significantly higher incidence of SIRS, fever, urosepsis requiring only additional antibiotics, and an increased postoperative hospitalization stay. Compared to Group2B, Group2A had similar rate of infectious complications. In addition, Group1B was associated with a significantly lower rate of positive pelvic urine culture (PUC +) than that of Group1A; whereas, there was similar rate of PUC + between Group2A and Group2B. UC-patients with N + WBC + should be treated with extended period of antibiotic administration, and a single dose of prophylactic antibiotic was sufficient for UC-patients with N - WBC + prior to PCNL. Despite UC, it is suggested to stratify pre-operative antibiotics tailored to individual patients to optimize its application.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antibiotics; Negative urine culture; Percutaneous nephrolithotomy; Renal stone

Mesh:

Substances:

Year:  2021        PMID: 33710365     DOI: 10.1007/s00240-021-01260-8

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  3 in total

Review 1.  Urosepsis--Etiology, Diagnosis, and Treatment.

Authors:  Nici Markus Dreger; Stephan Degener; Parviz Ahmad-Nejad; Gabriele Wöbker; Stephan Roth
Journal:  Dtsch Arztebl Int       Date:  2015-12-04       Impact factor: 5.594

Review 2.  Prevention of recurrent urinary tract infections.

Authors:  F M E Wagenlehner; W Vahlensieck; H W Bauer; W Weidner; H J Piechota; K G Naber
Journal:  Minerva Urol Nefrol       Date:  2013-03       Impact factor: 3.720

3.  The Evaluation of Risk Factors for Postoperative Infectious Complications after Percutaneous Nephrolithotomy.

Authors:  Tian Yang; Shenghua Liu; Jimeng Hu; Lujia Wang; Haowen Jiang
Journal:  Biomed Res Int       Date:  2017-02-02       Impact factor: 3.411

  3 in total
  3 in total

1.  Predictive accuracy of the modified SOFA score, SIRS criteria, and qSOFA score for uroseptic shock after mini-percutaneous nephrolithotomy.

Authors:  Meng Gao; Zewu Zhu; Minghui Liu; Jinbo Chen; Hequn Chen
Journal:  Urolithiasis       Date:  2022-02-24       Impact factor: 2.861

2.  Antibiotic prophylaxis for percutaneous nephrolithotomy: An updated systematic review and meta-analysis.

Authors:  Hae Do Jung; Kang Su Cho; Young Joon Moon; Doo Yong Chung; Dong Hyuk Kang; Joo Yong Lee
Journal:  PLoS One       Date:  2022-04-15       Impact factor: 3.240

3.  The antibiotic strategies during percutaneous nephrolithotomy in China revealed the gap between the reality and the urological guidelines.

Authors:  Shike Zhang; Gonghui Li; Ludong Qiao; Dehui Lai; Zhican He; Lingyue An; Peng Xu; Hans-Göran Tiselius; Guohua Zeng; Junhua Zheng; Wenqi Wu
Journal:  BMC Urol       Date:  2022-08-30       Impact factor: 2.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.